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BACKGROUND: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) contains crucial information about tumour
heterogeneity and the transport limitations that reduce drug efficacy. Mathematical modelling of drug delivery and cellular
responsiveness based on underutilised DCE-MRI data has the unique potential to predict therapeutic responsiveness for individual
patients.
METHODS: To interpret DCE-MRI data, we created a modelling framework that operates over multiple time and length scales and
incorporates intracellular metabolism, nutrient and drug diffusion, trans-vascular permeability, and angiogenesis. The computational
methodology was used to analyse DCE-MR images collected from eight breast cancer patients at Baystate Medical Center in
Springfield, MA.
RESULTS: Computer simulations showed that trans-vascular transport was correlated with tumour aggressiveness because increased
vessel growth and permeability provided more nutrients for cell proliferation. Model simulations also indicate that vessel density
minimally affects tissue growth and drug response, and nutrient availability promotes growth. Finally, the simulations indicate that
increased transport heterogeneity is coupled with increased tumour growth and poor drug response.
CONCLUSION: Mathematical modelling based on DCE-MRI has the potential to aid treatment decisions and improve overall cancer
care. This model is the critical first step in the creation of a comprehensive and predictive computational method.
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The ability to predict the response of a patient to chemother-
apeutic treatment is necessary to identify correct therapeutic
regiments and dosages (Lonning, 2007; Zahra et al, 2007). In breast
cancer, for example, the effectiveness of neoadjuvant chemo-
therapy varies dramatically among patients (Chuthapisith et al,
2006). Determining which patients will respond to therapy would
prevent unnecessary treatment and diminish life-threatening
delays until surgery. Two primary factors that reduce the efficacy
of chemotherapeutics are limited delivery and reduced cellular
responsiveness, both of which are associated with tumour
heterogeneity (Jain, 1998; Minchinton and Tannock, 2006).
Abnormal and inadequate vasculature coupled with diffusion
limitation results in reduced availability of nutrients, for example
glucose and oxygen (Jain, 1988; Vaupel et al, 1989). Cells located
away from vasculature do not traverse through the cell cycle,
become quiescent, and are less susceptible to cytotoxic drugs
(Gardner, 2000; Kim and Tannock, 2005). The effectiveness of
chemotherapeutic drugs is further reduced by inadequate delivery
and limited diffusion through different microenvironments
(Jain, 1999; Tannock et al, 2002; Minchinton and Tannock, 2006).
Information necessary to quantify therapeutic resistance can
be obtained by dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI), which measures the accessibility of small
molecules to different tumour regions (Tofts, 1997; Turetschek
et al, 2004; Feng et al, 2008). In gadopentetic acid (Gd-DTPA)-
based DCE-MRI, contrast agent is injected i.v. and signal
enhancement is measured as a function of location and time.
Following injection, Gd-DTPA fills the vascular space, diffuses into
the surrounding tissue, and is eventually washed out. Vasculature
density and permeability are calculated from local time profiles
using multi-compartment models (Tofts and Kermode, 1991;
Tofts, 1997; Harrer et al, 2004). DCE-MRI has the potential to
be a powerful tool for predicting therapeutic responsiveness
(Sorensen, 2006) because it is in common use and is readily
available (Chen et al, 2006; Ah-See et al, 2008). In previous clinical
studies DCE-MRI measurements have been shown to correlate
with change in tumour volume (Martincich et al, 2004; Hsiang
et al, 2007) and with responsiveness to neoadjuvant chemotherapy
(Padhani et al, 2006; Loo et al, 2008). Specifically, the transvascular
transport parameter (K
trans) has been shown to correlate with
therapeutic responsiveness (Hayes et al, 2002; Ah-See et al, 2008).
In addition, previous studies have shown that DCE-MRI measure-
ments correlate with microvascular density (Hawighorst et al,
1997; Su et al, 2003). It has also been suggested that DCE-MRI
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scould be used to indicate the efficacy of anti-angiogenic therapy
(Hylton, 2006). Changes in K
trans, measured 1 day after treatment
with cediranib, an anti-angiogenic therapy, have been shown to
predict overall and progression-free survival (Sorensen et al,
2009). Recently, it has also been shown that the heterogeneity of
masked wavelet decomposition coefficients in DCE-MR images is
a strong predictor of responsiveness to radiation treatment
(Prescott et al, 2010) and that MRI parameters for perfusion
heterogeneity and tumour volume are better predictors of tumour
recurrence and death than clinical prognostic factors (Mayr et al,
2010).
To obtain predictions for the therapeutic response of individual
patients, one needs to interpret spatially dependant transport
information from DCE-MRI. Mathematical models that include
molecular transport, cell growth, and drug response have the
potential to interpret DCE-MRI data and provide a basis for
patient-specific predictions. Previous mathematical models have
predicted tumour growth rate based on the mechanisms of
nutrient diffusion and cell growth and death (Adam and
Maggelakis, 1990; Ward and King, 1997; Araujo and McElwain,
2004). Tumour growth models have also been used to study the
effects of drug diffusion on tumour growth (Jackson and Byrne,
2000; Bertuzzi et al, 2003). Other more specific mathematical
models have, for example, predicted the effects of vascular
normalisation by anti-angiogenic drugs (Jain et al, 2007) and the
effects of paclitaxel transport on cancer cells (Kuh et al, 2000).
In previous work we built upon these models to show how
multiple nutrients interact to control cell growth and death
(Venkatasubramanian et al, 2006) and how transport properties
dictate the efficacy of cancer therapeutics (Venkatasubramanian
et al, 2008).
Here we describe a mathematical framework that incorporates
DCE-MRI data into a tumour growth model to predict therapeutic
response. We have used this computational method to test the
hypothesis that local transport properties can predict therapeutic
response. Specifically, we hypothesise that (1) increased trans-
vascular transport predicts improved theoretical response, and
(2) increased spatial heterogeneity predicts reduced theoretical
response. The drug response model is based on our previous
tumour models that integrate intracellular metabolism, nutrient
and drug diffusion, cell-cycle progression, cellular drug effects, and
drug pharmacokinetics (Venkatasubramanian et al, 2006, 2008).
The current model integrates information on local vascular
permeability and vessel density derived from DCE-MRI. The
model operates over multiple length scales, including cellular
(mm), vascular (100mm), voxel (mm), and whole tumour (cm); and
multiple time scales, including cellular diffusion (seconds),
gadolinium infusion (minutes), and tumour drug response
(weeks). The model was used to analyse DCE-MR images and
generate predictions for eight patients at Baystate Medical Center
in Springfield, MA. Because of its mechanistic basis, we believe
that this theoretical framework has potential to be a predictive
therapeutic tool for individualised therapy.
MATERIALS AND METHODS
Included in this study were eight female breast cancer patients
who were referred to the Baystate Breast MRI Center between
March 2006 and May 2007. Patients, with ages ranging from 40
to 73, were selected to include a diverse population based on tumour
staging and aggressiveness. The imaging procedure consisted
of (1) scanning each patient to establish an unenhanced image,
(2) administering 0.1mmolkg
 1 Gd-DTPA, and (3) scanning an
additional six times, with a spacing of approximately 2min. Ethical
approval for the study was granted by the institutional review
board at Baystate Health Systems (IRB07-013). All data were
acquired before the study as part of standard care procedures
and identifying information was removed to protect patient
confidentiality (as per 45 CFR 46.101(b)). The study followed all
HIPAA guidelines.
The procedure for determining therapeutic response from DCE-
MRI contained three major steps. First, a theoretical framework
was developed and simulations were run to generate relations
between transport parameters and local drug response (Figure 1).
Second, local transport parameters were determined for each stack
of MR images. Finally, local responses were calculated and
summed to determine the overall response of each tumour.
Model framework
To mechanistically interpret MRI data, the model integrated four
length scales: whole tumours, MRI voxels, tumour cords, and
individual cells (Figure 1A). MRI voxels are 600 600 3000mm
rectangular cuboids whose size is specified by spectrometer
resolution. Because the average spacing between blood vessels in
tumours is much less than these limiting dimensions, a set of
assumptions were made about the tissue inside each voxel. These
assumptions were necessary to interpret DCE-MRI transport
information and couple the disparate length scales. The primary
assumption was that the tissue within each voxel was uniform.
Although this is a considerable simplification, it is the only way to
connect MRI data to therapeutic predictions without specific
information about the vasculature geometry within each voxel. To
implement this assumption, we assumed each voxel to contain
multiple identical repeating Krogh tumour vessel cords (Krogh,
1919a,b), which are cylinders of tumour tissue surrounding a
central blood vessel (Figure 1A). Longitudinal gradients and the
space between cylinders were neglected. Neglecting this space has
previously been shown to have minimal effects (Groebe, 1995).
It was also assumed that there was no transport between voxels,
which could not be observed because of the coarse temporal
resolution of DCE-MRI. The computational model characterises
tumour behaviour by summing the predictions obtained for
individual component voxels (Figure 1A).
Two mechanisms affected tissue growth within voxels: (1) cell
growth, which increased cord width; and (2) angiogenesis, which
increased the number of cords (Figure 1B). The rates of cell growth
and death were controlled by the delivery of nutrients and drugs
from vessels into the interstitial space, as we have described
previously (Venkatasubramanian et al, 2006, 2008). These rates
were calculated by integrating the effects of nutrient and drug
diffusion, cell-cycle progression, intracellular metabolism, cellular
drug effects, and drug pharmacokinetics (Figure 1C; see Supple-
mentary Information). Cells consumed three nutrients: glucose,
oxygen, and lactate, whose uptake rates were dependant on
local concentration and the stoichiometry of glycolysis and the
TCA cycle (Venkatasubramanian et al, 2006). The time-varying
concentration of paclitaxel in the vessel following i.v. adminis-
tration was described by a three-compartment pharmaco-
kinetic model (Gianni et al, 1995). The cytotoxicity of paclitaxel
depended on the extracellular concentration and was assumed to
be saturable (Venkatasubramanian et al, 2008). Uniform effective
diffusion coefficients were assumed for all molecules. Spatial
transport heterogeneity was attributed to variations in vascular
permeability, which was determined by quantifying Gd-DTPA
transport.
Angiogenesis
Angiogenesis was modelled by increasing the number of cords in a
voxel (Figure 1B). Because all cords in a voxel were assumed to be
identical, it was not necessary to consider their arrangement, only
the number per voxel, o. Angiogenesis was controlled by the
diffusion of angiogenic factors (assumed to be predominantly
vascular endothelial growth factor, VEGF), produced by tumour
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scells in hypoxic microenvironments (Hockel and Vaupel, 2001).
The rate of angiogenesis was dependant on three parameters:
angiogenic sensitivity, a; the number of vessels, o; and the
concentration of VEGF at the vessel wall, CVEGF
vessel.
do
dt
¼ aoCvessel
VEGF ð1Þ
Angiogenic sensitivity, a, is a new parameter introduced here to
capture spatial variations in cellular response to hypoxia and
vessel response to VEGF. The production of VEGF was dependant
on local oxygen concentration in the interstitial space, COx.
DVEGF
1
r
q
qr
r
qCVEGF
qr
 
¼
Qmax
VEGFCOx
KHypoxia þ COx
ð2Þ
The diffusivity of VEGF, DVEGF; the maximum rate of VEGF
formation, QVEGF
max ; and the hypoxic sensitivity, KHypoxia, were
1.13 10
 6cm
2s
 1,2 . 9 5 10
 17pmolmm
 2s
 1,a n d1 0m mH gr e s -
pectively (Hockel and Vaupel, 2001; Mac Gabhann and Popel, 2005;
VEGF, lactate
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Figure 1 Components of tumour growth and drug response model. (A) The model framework incorporates four length scales: whole tumours, MRI
voxels, vascular cords, and individual cells. Tumours contain a collection of cuboid voxels, whose size was fixed by spectrometer resolution. Each voxel
contains a series of identical tumour cords, each consisting of tumour cells surrounding a central blood vessel. Nutrients (glucose, oxygen), anti-cancer
agents, and MRI contrast agents diffuse from the vessel outwards, whereas lactate and VEGF generated in the cord exterior diffuse towards the vessel.
Cell growth rate is variable with radius. Cell types typically arrange with proliferating cells close to the vessel, dead cells towards the periphery, and
an intermediate region of quiescent cells. (B) Two processes control tumour growth: increase in cord size and increase in cord number (angiogenesis).
Cord radius increases due to cell growth and decreases due to death from nutrient depletion or drug cytotoxicity. (C) Three additional biological
components are incorporated in the model framework: intracellular metabolism, cell growth dynamics, and drug pharmacokinetics. The metabolic
component integrates three nutrients: glucose, oxygen, and lactate, through glycolysis and the TCA cycle. The drug pharmacokinetic component contains
two compartments and rates for infusion, metabolism, absorption, and elimination. The cell growth component contains transition rates between three cell
types: proliferating, quiescent, and dead cells. Proliferating and quiescent cells die in low-nutrient or high-drug conditions. Proliferating cells either replicate
or become quiescent depending on nutrient availability. (D) A two-compartment pharmacokinetic model with a mass transfer coefficient, K
trans, describes
Gd-DTPA transport between vascular (fV) and extra-vascular (fev) spaces. A four-step process converts spatially dependant transport information from
DCE-MRI into tumour predictions: (1) a K
trans and fV parameter pair is measured for each MRI voxel; (2) each (K
trans, fV) parameter pair is converted into
permeability (P) and angiogenic sensitivity (a) using parameter maps based on simulation results; (3) subsequent (P, a) parameter pairs are similarly
converted into local growth rate (mG) and drug response (DV); and (4) local responses are summed to predict overall growth rate and drug responses for
entire tumours.
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sMac Gabhann et al, 2006). The concentration of VEGF in the vessel
wall was assumed to be proportional to the flux of VEGF across the
vessel lining (see Supplementary Information).
Tumour growth simulations
Overall tumour growth and drug response dynamics were deter-
mined by a four-step process (Figure 1D): (1) local transport para-
meters, K
trans and fV (vascular volume fraction), were calculated
for each voxel in a tumour as described below; (2) transport
parameter pairs were converted into equivalent parameter pairs
of angiogenic sensitivity, a, and average vessel permeability, P;
(3) a and P parameter pairs were used to determine the local rate
of cord growth, mG, and the relative decrease in volume due to
drug administration, DV; and (4) local rates were summed over all
included voxels to obtain overall tumour values.
To streamline tumour analysis, we generated maps between
parameter pairs. For each (K
trans, fV) pair there existed one unique
(a, P) pair and one unique (mG, DV) pair. The implementation of
parameter mapping rendered tumour analysis a rapid matrix
multiplication and element summation process. Parameter maps
were generated by simulating tumour cords with all physiological
feasible values of a and P and determining the corresponding
values of K
trans, fV, mG,a n dDV.T h ea and P grid consisted of 3600
points (60 on a side) spanning a values from 1 10
 5 to 1 10
1mM
per day and P-values from 1 10
 2 to 1 10
2cmmin
 1.
To calculate tumour growth, mG, and drug response, DV, we ran
simulations for each initiating a and P pair. Transport parameters,
K
trans and fV, were calculated from the final steady-state solutions.
Simulations were initialised with a vessel surrounded by a thin
layer of proliferating cells. Within each cord, volume increased and
decreased as a function of radius due to cell growth and death
as described above and in the Supplementary Information
(Venkatasubramanian et al, 2006, 2008). The total rate of voxel
volume change, dV/dt, was related to the rate of change in the
number of cords, do/dt, and the rate of change of the cord
thickness, dRcord/dt.
dV
dt
¼ pHR 2
cord
do
dt
þ o
dR2
cord
dt

ð3Þ
Here H is the arbitrary height of a voxel and is a parameter that
had no effect on simulation results. Simulations were run until the
rate of cord expansion, dRcord/dt, approached zero. This end point
reflects the assumption that at the time of MRI acquisition vessel
density in each voxel was not changing with time. Voxel vessel
density was calculated from the final cord radius: fV¼Rvessel
2 /Rcord
2 .
The radius of all vessels, Rvessel, was assumed to be constant
throughout all tumours and equal to 20mm (Konerding et al,
2001).
The transvascular transport parameter, K
trans, was determined
by computationally introducing Gd-DTPA into each cord. The
concentration in the blood plasma decreased according to the
vascular input function, which was assumed to be an exponential
function with a time constant of 6.94 (Tofts and Kermode, 1991).
The commonly used second biexponential time constant
(90.1min) (Tofts and Kermode, 1991) did not affect Gd-DTPA
concentration over the short investigated timescale. The rate of
Gd-DTPA extravasation was controlled by the vascular perme-
ability, P, and an effective tissue diffusivity of 2.6 10
 6cm
2s
 1
(Thelwall et al, 2001). The total Gd-DTPA concentration profile
was calculated for a 10min period. This profile was subsequently
used to calculate K
trans using the two-component method describe
below (Figure 1D).
Overall tumour volume was determined by summing up
the number of voxels within a tumour and multiplying by the
volume of each voxel. For growth and drug simulations, the
volume of each voxel was determined relative to its initial volume
(0.6mm 0.6mm 3mm). Tumour growth rate, mG, was found by
predicting tumour volume for 360 days at 60-day intervals and
fitting the values to an exponential function. Tumour drug
response was determined for each cord by introducing paclitaxel
for eight biweekly cycles. This schedule is similar to that used at
Baystate Medical Center for neoadjuvant therapy. The drug
response, DV, was defined as the volume after treatment relative
to the original volume.
Local transport parameters
Two transport parameters were determined from each DCE-MRI
data set using a two-compartment model (Figure 1D): the
transvascular transport rate constant, K
trans and the vascular
volume fraction, fV (Harrer et al, 2004; Hylton, 2006; Martel, 2006;
Zahra et al, 2007; Turnbull, 2009). To reduce signal noise, we
pre-processed all images: individual voxel enhancements were
averaged with eight neighbouring voxels. This smoothing reduced
spatial resolution but enabled analysis of the intrinsically noisy
images provided by the clinic. The concentration of Gd-DTPA in
each voxel was assumed to be linearly proportional to the voxel
signal enhancement, E, which was calculated by normalising the
intensity, I, by the initial, unenhanced intensity, I0, E¼(I I0)/I0
(Chuthapisith et al, 2006; Lonning, 2007; Zahra et al, 2007). In
this two-compartment model (see Supplementary Information)
the sum of Gd-DTPA in the vascular and extra-vascular spaces
contributed to the total measured signal enhancement (Figure 1D).
Mass flux between the compartments was assumed to be linearly
dependant on the concentration difference and the transvascular
transport parameter, K
trans (Tofts, 1997; Harrer et al, 2004).
The signal enhancement profile of every voxel in every image
was analysed individually using iterative optimisation. Values for
the two adjustable parameters, fV and K
trans, were tuned until
calculated enhancement profiles best matched measured profiles.
Parameter estimation was performed using least-squares analysis
and the Matlab optimisation routine fmincon. Tumour boundaries
were defined as regions with fV 42% or K
trans 40.005min
 1. All
completely surrounded interior regions were included and
disconnected regions 5 pixels and smaller were excluded. Methods
for the construction of parameter maps and whole tumour images
are described in Supplementary Information.
Hypothetical homogeneous and heterogeneous tumours
The effect of heterogeneity was investigated by comparing
predicted results for whole complex tumours to those with
averaged transport properties. The behaviour of hypothetical
homogeneous tumours was determined using a technique similar
to that currently used clinically: a tumour signal enhancement was
determined by averaging the signal enhancement of all voxels
within a defined tumour boundary. The resulting signal enhance-
ment time profile was analysed as described above to obtain
average values for K
trans and fV. These values were subsequently
converted into average growth rate and drug response.
To systematically test the effect of transport heterogeneity, we
calculated growth rate and drug response for a set of hypothetical
tumours with increasing K
trans variance. K
trans was assumed to
have a b-distribution with a mean value of 0.015min
 1, which is
the median value in the patient population. The relative variance
was increased from 0.1 to 1.75 to include all values observed in the
measured tumour set. The generation of hypothetical hetero-
geneous tumours is described in Supplementary Information. To
quantitatively compare K
trans variance in the patient population,
we normalized variances to eliminate the effect of different mean
values. Variances were normalised by average K
trans values and
responses were normalised by the growth rate and drug response
of homogeneous tumours with the same mean.
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sStatistical analysis
The existence of statistically significant correlations was deter-
mined by linearly regressing data and using one-factor ANOVA.
A correlation was significant if the slope of the regression was
significantly different from zero. Confidence intervals greater than
95% were considered significant.
RESULTS
Cord growth and drug response parameters
Growth rates and the drug responses of whole tumours were
determined by summing the behaviour of individual tumour
cords. Cord responses were determined over the entire range
of observed input parameters, a and P (Figure 2). Simulation
of the cord model with parameters a¼0.056mM per day and
P¼2.51cmmin
 1 show characteristics that were observed for all
cords (Figure 2A). Typically, cords grew in the absence of drug and
shrank in the presence of drug (Figure 2A). Tumour cord growth
was characterised by a fast exponential cell growth phase followed
by a slower exponential angiogenic phase (Figure 2A). Initially the
cord consisted of a single vessel surrounded by a thin layer of
proliferating cells. At early times cells were well nourished and
cord volume increased exponentially. As the cord grew, nutrient
limitations appeared in the periphery causing growth cessation
and cell death. Hypoxia in the periphery induced the production of
angiogenic factors and caused new cords to form.
Tumour cord drug response was evaluated by simulating the
administration of eight biweekly cycles of paclitaxel (Figure 2A).
This schedule was designed to be similar to a typical administra-
tion pattern of neoadjuvant therapy. Each treatment with paclitaxel
caused a reduction in volume followed by growth once drug had
cleared from the blood (Figure 2A). Typically, the first response to
drug was greatest and cord volume eventually stabilised with
subsequent treatments (Figure 2A). The drug response was
controlled by the combined effects of drug efficacy, drug transport
limitations, cell growth, and angiogenesis. The overall effect of the
8-week drug cycle was characterised by the difference between
initial and final volumes, DV.
Parameter maps were produced from model simulations to
interpret the transport parameters extracted from MRI (Figure 2B).
Maps were created between the inputs to the computational model
(a, P), the transport parameters (K
trans, fV), and the local responses
(mG, DV). Ultimately, direct maps between the directly measured
transport parameters (K
trans, fV) and local responses (mG, DV) were
created (Figure 2C), further simplifying analysis. This was possible
because the relationships between the parameter pairs were one-
to-one. White space on the maps represents regimes where cords
shrank and mathematical solutions were not attainable. Parameter
values in these regions were not observed in clinical tumours.
Several anticipated relationships were identified in the parameter
maps (Figure 2B). As expected, the overall transport coefficient,
K
trans, increased with increasing vessel permeability, P. Vessel
density, fV, increased with increasing angiogenic sensitivity, a, and
decreased with increasing permeability, P, because angiogenic
sensitivity reduced cord saturation size and permeability increased
nutrient supply to peripheral cells. Growth rate, mG, increased with
P and a because both increased nutrient availability.
Simulations of cord drug response, DV, generated two
unexpected relationships. First, fV had minimal effect on DV
(Figure 2C). It was anticipated that a greater drug supply would
have more effect on cord volume. The lack of response suggests
that increased re-growth compensated for increased death. Second,
the relationship between K
trans and DV was non-linear. At both low
and high values of K
trans drug response was less (Figure 2C, right).
The greatest drug response was observed at moderate values of
K
trans (Figure 2C, right).
Whole tumour analysis
Tumour growth rates and drug responses were calculated from
DCE-MR images for the eight patients in the study (Figures 3
and 4). For each tumour, multiple slices were acquired at five times
after Gd-DTPA administration. The images were processed to
generate signal enhancement profiles for each tumour voxel
(Figure 3B). These profiles were used to estimate local values
for the transport rate, K
trans, and vascular volume fraction, fV
(Figure 3A). Every observed tumour contained voxels with a wide
distribution of vasculature and transport values. Although the use
of a fixed AIF can lead to systematic errors (Tofts and Kermode,
1991; Buckley et al, 2004), the measured values for K
trans and fV
were consistent with previously reported values (Harrer et al,
2004). Regions of high transport did not necessarily correlate with
regions of high vessel density, which is also consistent with
previous results (Gillies et al, 2002). Tumour boundaries were
determined from the union of the transport and vessel density
images as described in Materials and Methods. The local transport
parameters (Figure 3A) and the parameter maps (Figure 2B and C)
were used to calculate unique local values for a, P, mG, and DV
(Figure 3C). By summing the behaviour of all voxels, we predicted
the growth rate of the entire tumour and the overall response to
eight cycles of drug administration (Figure 3D).
This analysis procedure was repeated for all eight patients in the
study (Figure 4). Generally, regions of rapid growth also had the
highest response to drug treatment (Figure 4A and B). Summing
the behaviour across all voxels predicted the response of whole
tumours (Figure 4C). Average growth rates and drug responses
were in the ranges 0.06–0.3 per month and 8–13% respectively.
When organised in order of increasing tumour size, neither growth
rate nor drug response correlated with size (Figure 4C and D).
To investigate how heterogeneity affected predicted outcomes,
we used average signal enhancement profiles to simulate homo-
geneous tumour behaviour (Figure 4D). Averaging the signal
enhancement underestimated growth rate and inaccurately pre-
dicted drug response trends. The predicted growth rates for the
homogenous tumours were in the range 0.03–0.06 per month,
which was B20% of values obtained from full voxel-by-voxel
analysis. For some tumours, homogeneous analysis considerably
underestimated drug response (patients 2, 3, 6, and 7) and for
others it considerably overestimated response (patients 4 and 8).
Correlations between parameters and outcomes
Of the four input parameters (K
trans, fV, a,a n dP)t h et r a n s p o r t
parameter, K
trans, had the strongest correlation with the predictive
responses (mG and DV; Figure 5). In the patient population,
simulations predicted that tumours with higher average K
trans values
would have significantly (Po0.05) higher growth rates and better
responses to chemotherapy (Figure 5A). The correlation coefficients
between K
trans and mG and DV were 0.82 and 0.97 respectively. This
trend was also observed on the voxel scale; tumour regions with high
K
trans values (Figure 5B) also had high growth rates and drug
responses (Figure 4A and B). The global effect of the input
parameters on responses was further quantified by analysing
hypothetical homogeneous tumours. These hypothetical tumours
had single values of K
trans and fV within the range of values measured
in the patient population (Figure 5A; Supplementary Figure S1). The
coefficients of determination between the parameters K
trans, P, fV,
and a and the drug response, DV, were 0.90, 0.57, 0.096 and 0.04
respectively, indicating that K
trans is considerably more predictive
than the other three parameters (see Supplementary Information).
Effect of heterogeneity on prediction of drug response
Heterogeneity significantly increased tumour growth rate and
decreased drug response (Figure 5C and D). Because it was the
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spredominant parameter, tumour heterogeneity was characterised
by the standard deviation of K
trans, sK. The relative standard
deviation of K
trans in the patient population ranged from
approximately 0.5 to 1.5 (Supplementary Figure S1). To analyse
the effect of heterogeneity a set of hypothetical tumours was
created with constant mean K
trans and fV values and a range of
values for the standard deviation of K
trans. In this hypothetical set,
increasing the standard deviation of K
trans increased growth rate
and decreased drug response (Figure 5C). An identical pattern was
observed in the patient population: increasing the standard
deviation of K
trans significantly increased growth rate (Po0.05)
and decreased drug response (Po0.05; Figure 5D). The correlation
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Figure 2 Tumour simulation results and parameter maps. (A) Representative growth and drug response from a single tumour simulation with parameters
a¼0.056mM per day and P¼2.51cmmin
 1. Growth was characterised by an initial increase in cord radius followed by a period of increasing cord number
due to angiogenesis. Response to eight biweekly paclitaxel administration cycles (arrows) was characterised by initial shrinkage followed by re-growth after
drug washout. Drug response (DV) was defined as the relative difference between the initial and final volumes at the end of 16 weeks. (B) Parameter maps
from P and a to K
trans, fV, mG and DV. The units of K
trans and mG are min
 1 and per month, respectively; fV and DV are dimensionless. (C) Parameter maps
directly from K
trans and fV to mG and DV.
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scoefficients between sK and dmG and dDV were 0.88 and  0.92
respectively. The mean K
trans value and the standard deviation of
K
trans had similar effects on growth rate but opposite effects on drug
response. Increasing the mean and standard deviation both increased
growth rate. However, increasing the mean improved response and
increasing the standard deviation decreased response.
DISCUSSION
Here we describe a predictive multi-scale tumour model that
incorporates drug transport, angiogenesis, pharmacokinetics, and
intracellular metabolism. A method was developed to rapidly
determine transport parameters from individual patient DCE-MRI
acquired in a clinical setting. Angiogenesis was modelled by
extending the Krogh model to include formation of new blood
vessels. The model framework introduced a new parameter, a,t o
describe the sensitivity of cells and vessels to different levels of
oxygen and VEGF. The inclusion of this angiogenic sensitivity
accounted for variations in vessel densities observed across
tumours. Without its inclusion all tumour cords would have
saturated at the same external radius. The model framework also
predicts numerous testable tumour characteristics, including local
oxygen and glucose concentrations, rates of cell proliferation, and
the extent of necrosis. These predictions are useful because they
can be tested (by histology or PET, for example) and because they
begin to provide a mechanistic connection between imaging data
and drug efficacy.
Because the mathematical model describes general physiological
mechanisms, it has the potential to be generalisable to other
treatments and tumour sites. Angiogenesis, intracellular meta-
bolism, and tissue growth are aspects common to all solid tumours.
Generalisability is supported by recent results showing that in a
different site, glioblastoma, K
trans strongly correlates with overall
survival and K
trans heterogeneity can distinguish between respond-
ing and non-responding patients (Sorensen et al, 2009). Complete
validation of the model’s generalisability will require further
clinical investigations.
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Figure 3 Whole tumour predictions for growth and drug response based on local DCE-MRI data. (A) Images of local K
trans and fV values for a
representative MRI slice from patient 2. The units of K
trans are min
 1 and fV is dimensionless. Scale bar is 5mm. (B) Representative DCE-MRI signal intensity
profile for one voxel within the tumour of patient 2. (C) Images of local P, a, mG, and DV values for the representative slice in (B). Colour scales are linear
for P, mG, and DV and log scale for a. The units of P, a, and mG are cmmin
 1,m M per day, and per month, respectively; and DV is dimensionless. Scale
bar is 5mm. (D) Tumour growth and drug response predictions for patient 2 obtained by summing the behaviour of all voxels in all slices comprising
the tumour.
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sPredominance of K
trans
Of the parameters used in the model framework to characterise
tumour behaviour, the local trans-vascular transport rate, K
trans,
had the greatest effect on tumour growth and drug response.
Simulations showed that responses were more dependant on K
trans
than vascular density, fV (Figure 2C, left), vascular permeability, P,
or angiogenic sensitivity, a. The predominance of K
trans can be also
seen in the banding pattern of the parameter maps. In the maps
from a and P to K
trans, mG, and DV (Figure 2B) similar bands run
from the upper left to the lower right. These patterns indicate that
K
trans captures a combined effect of permeability and angiogenic
sensitivity that better predicts mG and DV than either parameter
alone.
The physiological nature of the model enabled a mechanistic
explanation of these relations between parameters (Figure 6).
The connection between tumour growth (mG) and K
trans (Figure 2C,
left) was a consequence of the complex dependence of K
trans
on vessel density, fV, and permeability, P (Figure 6A). Cords
with high K
trans values transported more material into tumour
tissue because of either higher vessel density (high fV) or greater
leakiness (high P). At any given K
trans value, high vessel density
was associated with low permeability, and low density was
associated with high permeability (Figure 6A). When translated
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Figure 4 Heterogeneity of growth rate and drug response calculated for eight patients. (A, B). Representative slices showing local values of mG (A) and
DV (B) for eight patients arranged in order of increasing size. Regions outside the identified tumour are blackened. Scale bar is 5mm for patients 1–3 and
2cm for patients 4–8. (C) Growth rate (mG) and drug response (DV) predictions were determined by summing local behaviours in (A) and (B) for all slices
in each tumour. (D) Predictions for homogeneous tumours with single K
trans and fV values calculated from signal intensity profiles averaged across whole
tumours.
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trans (sK) in a hypothetical heterogeneous tumour increased relative growth rate (dmG) and decreased
relative drug response (dDV). Relative growth rate is defined as the difference in growth between the heterogeneous tumour and a hypothetical
homogeneous tumour with the same average K
trans value. Relative drug response is defined similarly. (D) For the eight patients, an increasing standard
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sinto tumour growth, poor delivery due to low vessel density was
compensated by high permeability, resulting in a similar growth
rate to cords with high vessel density and low permeability
(Figure 2C, left). However, higher values of K
trans represented
cords with both greater density and permeability (Figure 6A),
which therefore received more nutrients and grew faster
(Figure 2C, left).
The relation between K
trans and drug response was more
complicated than tumour growth. The effect of K
trans on DV was
non-linear and showed a maximum value for which there was an
optimal drug response (Figure 2C, right and Figure 6B). This
optimum was caused by the interaction of two competing factors
observed in the cord simulations: (1) shrinkage in the presence of
drug and (2) re-growth after drug washout. At low values of K
trans,
few cells were proliferating (Figure 6C) and were not responsive to
drug. At high values of K
trans, tumour shrinkage was limited
because drug-induced cell death was outpaced by tissue re-growth,
fueled by abundant nutrients (Figure 6D).
Heterogeneity
Model simulations suggest that monitoring average transport
behaviour is insufficient and that it is important to quantify
tumour heterogeneity to predict drug response. Heterogeneity is
important for two reasons. First, including only the average
transport rate in our simulations poorly predicted the tumour drug
response (Figure 4). These simulation results suggest that
determining both the average and standard deviation of K
trans is
necessary to predict drug response accurately. Second, the mean
value of K
trans had a mixed effect but the variance was doubly
detrimental. Tumours with high average K
trans values had fast
growth rates but increased drug responses (Figure 5A). Highly
heterogeneous tumours, however, grew fast and responded poorly
to therapy (Figure 5C and D).
These seemingly contradictory effects were caused by different
mechanisms. Heterogeneous tumours had higher growth rates because
more regions were well supplied with nutrients. The model predicted
that these regions grew more than an order of magnitude faster than
regions with a nominal supply of nutrients (Figure 6C and D), and had
a dominant effect on the overall tumour growth rate. Heterogeneous
tumours had poor drug response because a large fraction of the
tumours were not proliferating and were not responsive to drug
(Figure 6C). The increase in volume reduction seen in regions with
higher drug concentrations was small and did not compensate for the
minimal response in large non-responsive regions.
CONCLUSION
We have developed a model framework that integrates individual
patient data into a tumour growth model, which accounts for
intracellular metabolism, nutrient and drug diffusion, trans-
vascular permeability, and angiogenesis. To the best of our
knowledge this is the first report on the acquisition of transport
parameters from individual patient DCE-MRI and their use in a
predictive computational model. Simulations with this model
suggested that K
trans is correlated with tumour aggressiveness
because increased vessel growth and permeability provide more
nutrients for cell proliferation. Simulations also suggested that
tumour heterogeneity is a critical parameter to monitor because of
its association with increased tumour growth and poor drug
response. In addition the model simulations produced multiple
testable hypotheses. For example the simulations suggested that
(1) vessel density minimally affects tissue growth and drug
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Figure 6 Physical characteristics of tumour cords as predicted by simulation. (A) At any given K
trans value, permeability and vessel density were
inversely related. Increasing K
trans increased both P and fV.( B) The relationship between K
trans and DV (shown at fV¼0.05) possessed an optimal drug
response. (C, D) The cord growth rate (C) and the average cord glucose concentration (D) were both strongly dependant on K
trans. Relations are shown at
fV¼0.05.
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sresponse, (2) nutrient availability drives tissue growth, and
(3) angiogenic rates vary across tumours. All the results suggest
that DCE-MR images contain critical information that can predict
therapeutic efficacy and that mathematically modelling has the
potential to improve treatment decisions. We believe that this
model is a first step towards the creation of a comprehensive
computational method that will provide individual therapeutic
predictions based on imaging data. Continued development of
these methods has the potential to provide individualised patient
predictions and improve overall cancer care.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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